Detalhe da pesquisa
1.
GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Antimicrob Agents Chemother
; 62(5)2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29463535
2.
Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.
Antimicrob Agents Chemother
; 59(4): 1895-904, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25583709
3.
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
Antimicrob Agents Chemother
; 58(7): 3679-88, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24752271
4.
Surgeon case volume and continence recovery following radical prostatectomy: a systematic review.
ANZ J Surg
; 91(4): 521-529, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33319438
5.
Surgeon Experience and Erectile Function After Radical Prostatectomy: A Systematic Review.
Sex Med Rev
; 9(4): 650-658, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34219004
6.
A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance.
Glob Health Med
; 1(1): 36-48, 2019 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33330753
7.
Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.
Sci Rep
; 9(1): 4828, 2019 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30886166